Table of ContentsView AllTable of ContentsSigns an SymptomsCauses and Risk FactorsDiagnosisTreatmentPreventionFrequently Asked Questions
Table of ContentsView All
View All
Table of Contents
Signs an Symptoms
Causes and Risk Factors
Diagnosis
Treatment
Prevention
Frequently Asked Questions
Non-sustained ventriculartachycardia(NSVT, or non-sustained V-tach) is anabnormal heart rhythm(arrhythmia) that starts in thelower chambers of the heart(ventricles). NSVT is three or more consecutive heartbeats at a rate of more than 100 beats per minute (bpm) and lasts for less than 30 seconds.
An episode of NSVT can go away on its own, so it is not considered as dangerous assustained ventricular tachycardia(SVT), which lasts more than 30 seconds.
Non-sustained VT can be completely harmless in some people, but it’s still important to find out why you have NSVT.
You should also find out if you have risk factors that make you more likely to have NSVT, such as heart disease, electrolyte imbalances, drug use, and taking certain medications.
This article will go over the signs and symptoms of NSVT as well as how it’s diagnosed and treated.
NSVT Symptoms and Signs
NSVT is an episode of ventricular tachycardia that:
Most of the time, NSVT does not cause any symptoms. If it does,palpitations—feeling a fast or irregular heartbeat—can be the only symptom a person has of NSVT. The palpitations can also be associated with trouble breathing or chest pain.
Occasionally, NSVT can causelightheadednessand/ordizziness. Rarely, loss of consciousness (fainting orsyncope) may happen with NSVT.
Verywell / JR Bee
When to Seek Medical Attention
NSVT can be harmless, but it can also be a sign of a more serious sustained ventricular arrhythmia and a risk for sudden death.
It’s important to see your healthcare provider if you are having symptoms like:
Call 911 or go to the ER if you are having:
Chest Pain: When Symptoms Are and Aren’t Heart-Related
NSVT Risk Factors and Causes
NSVT can be related to a problem with the structure or function of the heart (which a person may not realize they have).
NSVT can also be related to problems with the electrical signaling in the heart that helps it beat.
These problems can lead to more dangerous arrhythmias, such asventricular fibrillation.This is when the heart stops beating as it should and starts to quiver instead, causing a person to go into cardiac arrest.
It’s not always easy or possible to change structural or electrical heart problems. However, some risk factors for NSVT are things that you can change.
Structural Heart Disease
The kinds of heart disease most commonly associated with NSVT are:
Can NSVT cause a stroke?Some research has suggested that NSVT may increase a person’s risk for having a stroke.
Can NSVT cause a stroke?
Some research has suggested that NSVT may increase a person’s risk for having a stroke.
NSVT is also seen with:
Electrical Instability
The most common is repetitive monomorphic ventricular tachycardia (RMVT).
RMVT is a disorder that almost only occurs in young to middle-aged people who do not have structural heart disease.
Reversible Risk Factors
Many factors that trigger NSVT are things you can take steps to fix, including:
When Should I Worry About NSVT?
How Is It Diagnosed?
NSVT usually does not cause symptoms and is instead found during anelectrocardiogram (ECG)that’s being done for another reason.
If a person is having symptoms, NSVT might be diagnosed during anambulatory ECG monitoring system.
Heart Rhythm Monitoring
Ambulatory ECG systems record the electrical activity of your heart over days, weeks, or even years. This longer monitoring period allows for heart arrhythmias that may come and go, like NSVT, to be seen and recorded.
A provider who specializes in heart conditions (cardiologist) will look at the recordings from the ambulatory ECG system to see if NSVT or another arrhythmia is on them.
The Holter monitor is typically worn for 24 to 48 hours or longer and records your heart rhythm continuously.
Additional Testing
If NSVT is diagnosed, your provider will do more testing to figure out if there are any reversible risk factors you could work on.
Your provider can do a medical history/physical exam, blood tests like abasic metabolic panel,complete blood count, orthyroid-stimulating hormone (TSH).
Your provider will also check you for any underlying heart problems or diseases. Tests they can use include:
If the results from one or more of these tests show that you have heart disease (such as coronary artery disease), your treatment will be focused on that condition.
If no heart disease is found, you might need to see a heart rhythm specialist (cardiac electrophysiologist) to check if you have RMVT and other conditions.
Non-Sustained VT vs. Sustained VT
Non-Sustained VTThe arrhythmia lasts less than 30 secondsDoes not typically cause symptomsIs often harmlessCan be from a structural or electrical heart issueMay not need treatment if there are no symptomsSustained VTThe arrhythmia lasts longer than 30 secondsMay cause fainting or loss of consciousnessCan lead to sudden deathMost likely related to a structural heart issueTreated with an intense shock to reset the heart’s rhythm and/or medications
Non-Sustained VTThe arrhythmia lasts less than 30 secondsDoes not typically cause symptomsIs often harmlessCan be from a structural or electrical heart issueMay not need treatment if there are no symptoms
The arrhythmia lasts less than 30 seconds
Does not typically cause symptoms
Is often harmless
Can be from a structural or electrical heart issue
May not need treatment if there are no symptoms
Sustained VTThe arrhythmia lasts longer than 30 secondsMay cause fainting or loss of consciousnessCan lead to sudden deathMost likely related to a structural heart issueTreated with an intense shock to reset the heart’s rhythm and/or medications
The arrhythmia lasts longer than 30 seconds
May cause fainting or loss of consciousness
Can lead to sudden death
Most likely related to a structural heart issue
Treated with an intense shock to reset the heart’s rhythm and/or medications
NSVT Treatment
NSVT does not always need to be treated. If it does, managing NSVT will depend on the underlying cause of the arrhythmia and whether you have symptoms.
If you have no heart disease and no symptoms, no treatment is needed other than following up with your provider routinely or letting them know if anything changes with your health.
NSVT in people with a healthy heart is usually considered harmless and not something that needs treatment.
Medications
If you do get symptoms from NSVT, medications might be able to help—for example,beta-blockers,calcium channel blockers, orPacerone(amiodarone).
Amiodarone works to keep your heart in a regular rhythm (anantiarrhythmic drug).
Flecainideand Betapace (sotalol) are also antiarrhythmic drugs, but they are not usually recommended to treat NSVT (especially if the NSVT happens because of a heart attack).
Antiarrhythmic drugs can be used in certain cases when a person has severe symptoms and is under the care of an electrophysiologist.
Ablation Therapy
For people with severe symptoms or people who cannot tolerate or are not being helped b anti-arrhythmic drugs,ablation therapymight be an option.This treatment uses heat or cold energy to destroy the part of the heart that is thought to be the source of abnormal electrical signals.
Ablation therapy is successful at treating NSVT around 80% of the time.
Implantable Cardioverter-Defibrillator
NSVT poses an increased risk of cardiac arrest and sudden death if it occurs with coronary artery disease or heart failure—especially in people withhypertrophic cardiomyopathy.
With these conditions, the risk is from the reduced flow of blood from the left ventricle (ejection fraction) more than from NSVT. To reduce the risk, animplantable cardioverter-defibrillator(ICD) might be recommended.
An ICD is a battery-operated device that is put under the skin on your chest. It monitors the rhythm of your heart and delivers mild electrical currents or shocks if the rhythm becomes abnormal.
NSVT cannot be prevented, but some heart conditions that cause it can be. You can also take steps to reduce your risk factors for NSVT.
To optimize your heart health and lower the risk for NSVT, you can make some lifestyle changes:
Arrhythmias Healthcare Provider Discussion GuideGet our printable guide for your next healthcare provider’s appointment to help you ask the right questions.Download PDFEmail AddressSign UpThank you, {{form.email}}, for signing up.There was an error. Please try again.
Get our printable guide for your next healthcare provider’s appointment to help you ask the right questions.
Download PDF
Email AddressSign UpThank you, {{form.email}}, for signing up.There was an error. Please try again.
Sign Up
Thank you, {{form.email}}, for signing up.
There was an error. Please try again.
Summary
Non-sustained ventricular tachycardia (NSVT) is a kind of heart arrhythmia that usually stops within 30 seconds. In most people, it doesn’t cause any symptoms and is often harmless. In some people, it can develop into a more serious kind of heart problem.
NSVT may happen in healthy people or people with serious heart disease. It can be diagnosed with special tests to check the heart’s functioning. People with NSVT that do not have any symptoms may not need any treatment. People with heart disease or severe symptoms can be treated with procedures and medications.
While NVST can’t necessarily be prevented, lifestyle changes that support heart health can be helpful. If you or a loved one is diagnosed with NSVT, see a cardiologist for an assessment.
Frequently Asked QuestionsNSVT is not always a reason to worry but it could increase your risk of cardiac arrest and sudden death. If you have an underlying heart condition, your risk is even greater. Talking to your provider about making lifestyle changes and getting treatment to reduce your risk can help prevent these outcomes.Learn MoreTypes of Heart DiseaseYou should ask your provider if you can safely exercise with NSVT.Since getting regular physical activity is important for cardiovascular health, it could be a key part of your management plan.
NSVT is not always a reason to worry but it could increase your risk of cardiac arrest and sudden death. If you have an underlying heart condition, your risk is even greater. Talking to your provider about making lifestyle changes and getting treatment to reduce your risk can help prevent these outcomes.Learn MoreTypes of Heart Disease
NSVT is not always a reason to worry but it could increase your risk of cardiac arrest and sudden death. If you have an underlying heart condition, your risk is even greater. Talking to your provider about making lifestyle changes and getting treatment to reduce your risk can help prevent these outcomes.
Learn MoreTypes of Heart Disease
You should ask your provider if you can safely exercise with NSVT.Since getting regular physical activity is important for cardiovascular health, it could be a key part of your management plan.
20 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Marine JE.Nonsustained ventricular tachycardia in the normal heart: risk stratification and management.Card Electrophysiol Clin.2016 Sep;8(3):525-43. doi:10.1016/j.ccep.2016.04.003Al-Khatib SM, Stevenson WG, Ackerman MJ, et al.2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society.Circulation. 2018;138(13):e190-e252. doi:10.1016/j.hrthm.2017.10.035Cronin EM, Bogun FM, Maury P, et al.2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.Heart Rhythm.2020 Jan;17(1):e2-e154. doi:10.1016/j.hrthm.2019.03.002Lin CY, Chang SL, Chung FP, et al.Long-term outcome of non-sustained ventricular tachycardia in structurally normal hearts.PLoS One. 2016;11(8):e0160181. doi:10.1371/journal.pone.0160181Harris P, Lysitsas D.Ventricular arrhythmias and sudden cardiac death.BJA Educ. 2016;16(7):221-229. doi:10.1093/bjaed/mkv056Jamil HA, Mohammed SA, Gierula J, et al.Prognostic significance of incidental nonsustained ventricular tachycardia detected on pacemaker interrogation.Am J Cardiol. 2019;123(3):409-413. doi:10.1016/j.amjcard.2018.10.040Hammersley DJ, Halliday BP.Sudden cardiac death prediction in non-ischemic dilated cardiomyopathy: a multiparametric and dynamic approach.Curr Cardiol Rep. 2020;22(9):85. doi:10.1007/s11886-020-01343-9Lin CY, Chang SL, Chung FP, et al.Long-term outcome of non-sustained ventricular tachycardia in structurally normal hearts.PLoS One. 2016;11(8):e0160181. Published 2016 Aug 22. doi:10.1371/journal.pone.0160181Priori SG, Blomström-Lundqvist C, Mazzanti A, et al.2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.Eur Heart J. 2015;36(41):2793-2867. doi:10.1093/eurheartj/ehv316Ommen SR, Mital S, Burke MA, et al.2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2020;142(25):e558–e631. doi:10.1161/CIR.0000000000000937Wang C, Ju W, Chen H, et al.The clinical and electrophysiological characteristics of nonsustained repetitive monomorphic ventricular tachycardia from the left His‐Purkinje system.Pacing Clin Electrophysiol. 2020;43(10):1149-1155. doi:10.1111/pace.14055UpToDate.Ventricular tachycardia in the absence of apparent structural heart disease.Kohno R, Abe H, Benditt DG.Ambulatory electrocardiogram monitoring devices for evaluating transient loss of consciousness or other related symptoms.J Arrhythm. 2017 May;33(6):583-589. doi:10.1016/j.joa.2017.04.012Li X, Yao Y, Chen Z, et al.Thyroid‐stimulating hormone within the normal range and risk of major adverse cardiovascular events in nonischemic dilated cardiomyopathy patients with severe left ventricular dysfunction.Clin Cardiol. 2019;42(1):120-128. doi:10.1002/clc.23117ScienceDirect.Sustained ventricular tachycardia.Katritsis DG, Zareba W, Camm AJ.Nonsustained ventricular tachycardia.J Am Coll Cardiol. 2012;60(20):1993-2004. doi:10.1016/j.jacc.2011.12.063Nof E, Stevenson WG, John RM.Catheter ablation for ventricular arrhythmias.Arrhythm Electrophysiol Rev.2013 Apr;2(1):45–52. doi:10.15420/aer.2013.2.1.45Arnett DK, Blumenthal RS, Albert MA, et al.2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2019 Sep 10;140(11):e596-e646. doi:10.1161/CIR.0000000000000678Marine JE.Nonsustained ventricular tachycardia in the normal heart: risk stratification and management.Card Electrophysiol Clin. 2016;8(3):525-543. doi:10.1016/j.ccep.2016.04.003Marine JE, Shetty V, Chow GV, et al.Prevalence and prognostic significance of exercise-induced nonsustained ventricular tachycardia in asymptomatic volunteers: BLSA (Baltimore Longitudinal Study of Aging).J Am Coll Cardiol. 2013;62(7):595-600. doi:10.1016/j.jacc.2013.05.026
20 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Marine JE.Nonsustained ventricular tachycardia in the normal heart: risk stratification and management.Card Electrophysiol Clin.2016 Sep;8(3):525-43. doi:10.1016/j.ccep.2016.04.003Al-Khatib SM, Stevenson WG, Ackerman MJ, et al.2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society.Circulation. 2018;138(13):e190-e252. doi:10.1016/j.hrthm.2017.10.035Cronin EM, Bogun FM, Maury P, et al.2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.Heart Rhythm.2020 Jan;17(1):e2-e154. doi:10.1016/j.hrthm.2019.03.002Lin CY, Chang SL, Chung FP, et al.Long-term outcome of non-sustained ventricular tachycardia in structurally normal hearts.PLoS One. 2016;11(8):e0160181. doi:10.1371/journal.pone.0160181Harris P, Lysitsas D.Ventricular arrhythmias and sudden cardiac death.BJA Educ. 2016;16(7):221-229. doi:10.1093/bjaed/mkv056Jamil HA, Mohammed SA, Gierula J, et al.Prognostic significance of incidental nonsustained ventricular tachycardia detected on pacemaker interrogation.Am J Cardiol. 2019;123(3):409-413. doi:10.1016/j.amjcard.2018.10.040Hammersley DJ, Halliday BP.Sudden cardiac death prediction in non-ischemic dilated cardiomyopathy: a multiparametric and dynamic approach.Curr Cardiol Rep. 2020;22(9):85. doi:10.1007/s11886-020-01343-9Lin CY, Chang SL, Chung FP, et al.Long-term outcome of non-sustained ventricular tachycardia in structurally normal hearts.PLoS One. 2016;11(8):e0160181. Published 2016 Aug 22. doi:10.1371/journal.pone.0160181Priori SG, Blomström-Lundqvist C, Mazzanti A, et al.2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.Eur Heart J. 2015;36(41):2793-2867. doi:10.1093/eurheartj/ehv316Ommen SR, Mital S, Burke MA, et al.2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2020;142(25):e558–e631. doi:10.1161/CIR.0000000000000937Wang C, Ju W, Chen H, et al.The clinical and electrophysiological characteristics of nonsustained repetitive monomorphic ventricular tachycardia from the left His‐Purkinje system.Pacing Clin Electrophysiol. 2020;43(10):1149-1155. doi:10.1111/pace.14055UpToDate.Ventricular tachycardia in the absence of apparent structural heart disease.Kohno R, Abe H, Benditt DG.Ambulatory electrocardiogram monitoring devices for evaluating transient loss of consciousness or other related symptoms.J Arrhythm. 2017 May;33(6):583-589. doi:10.1016/j.joa.2017.04.012Li X, Yao Y, Chen Z, et al.Thyroid‐stimulating hormone within the normal range and risk of major adverse cardiovascular events in nonischemic dilated cardiomyopathy patients with severe left ventricular dysfunction.Clin Cardiol. 2019;42(1):120-128. doi:10.1002/clc.23117ScienceDirect.Sustained ventricular tachycardia.Katritsis DG, Zareba W, Camm AJ.Nonsustained ventricular tachycardia.J Am Coll Cardiol. 2012;60(20):1993-2004. doi:10.1016/j.jacc.2011.12.063Nof E, Stevenson WG, John RM.Catheter ablation for ventricular arrhythmias.Arrhythm Electrophysiol Rev.2013 Apr;2(1):45–52. doi:10.15420/aer.2013.2.1.45Arnett DK, Blumenthal RS, Albert MA, et al.2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2019 Sep 10;140(11):e596-e646. doi:10.1161/CIR.0000000000000678Marine JE.Nonsustained ventricular tachycardia in the normal heart: risk stratification and management.Card Electrophysiol Clin. 2016;8(3):525-543. doi:10.1016/j.ccep.2016.04.003Marine JE, Shetty V, Chow GV, et al.Prevalence and prognostic significance of exercise-induced nonsustained ventricular tachycardia in asymptomatic volunteers: BLSA (Baltimore Longitudinal Study of Aging).J Am Coll Cardiol. 2013;62(7):595-600. doi:10.1016/j.jacc.2013.05.026
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Marine JE.Nonsustained ventricular tachycardia in the normal heart: risk stratification and management.Card Electrophysiol Clin.2016 Sep;8(3):525-43. doi:10.1016/j.ccep.2016.04.003Al-Khatib SM, Stevenson WG, Ackerman MJ, et al.2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society.Circulation. 2018;138(13):e190-e252. doi:10.1016/j.hrthm.2017.10.035Cronin EM, Bogun FM, Maury P, et al.2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.Heart Rhythm.2020 Jan;17(1):e2-e154. doi:10.1016/j.hrthm.2019.03.002Lin CY, Chang SL, Chung FP, et al.Long-term outcome of non-sustained ventricular tachycardia in structurally normal hearts.PLoS One. 2016;11(8):e0160181. doi:10.1371/journal.pone.0160181Harris P, Lysitsas D.Ventricular arrhythmias and sudden cardiac death.BJA Educ. 2016;16(7):221-229. doi:10.1093/bjaed/mkv056Jamil HA, Mohammed SA, Gierula J, et al.Prognostic significance of incidental nonsustained ventricular tachycardia detected on pacemaker interrogation.Am J Cardiol. 2019;123(3):409-413. doi:10.1016/j.amjcard.2018.10.040Hammersley DJ, Halliday BP.Sudden cardiac death prediction in non-ischemic dilated cardiomyopathy: a multiparametric and dynamic approach.Curr Cardiol Rep. 2020;22(9):85. doi:10.1007/s11886-020-01343-9Lin CY, Chang SL, Chung FP, et al.Long-term outcome of non-sustained ventricular tachycardia in structurally normal hearts.PLoS One. 2016;11(8):e0160181. Published 2016 Aug 22. doi:10.1371/journal.pone.0160181Priori SG, Blomström-Lundqvist C, Mazzanti A, et al.2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.Eur Heart J. 2015;36(41):2793-2867. doi:10.1093/eurheartj/ehv316Ommen SR, Mital S, Burke MA, et al.2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2020;142(25):e558–e631. doi:10.1161/CIR.0000000000000937Wang C, Ju W, Chen H, et al.The clinical and electrophysiological characteristics of nonsustained repetitive monomorphic ventricular tachycardia from the left His‐Purkinje system.Pacing Clin Electrophysiol. 2020;43(10):1149-1155. doi:10.1111/pace.14055UpToDate.Ventricular tachycardia in the absence of apparent structural heart disease.Kohno R, Abe H, Benditt DG.Ambulatory electrocardiogram monitoring devices for evaluating transient loss of consciousness or other related symptoms.J Arrhythm. 2017 May;33(6):583-589. doi:10.1016/j.joa.2017.04.012Li X, Yao Y, Chen Z, et al.Thyroid‐stimulating hormone within the normal range and risk of major adverse cardiovascular events in nonischemic dilated cardiomyopathy patients with severe left ventricular dysfunction.Clin Cardiol. 2019;42(1):120-128. doi:10.1002/clc.23117ScienceDirect.Sustained ventricular tachycardia.Katritsis DG, Zareba W, Camm AJ.Nonsustained ventricular tachycardia.J Am Coll Cardiol. 2012;60(20):1993-2004. doi:10.1016/j.jacc.2011.12.063Nof E, Stevenson WG, John RM.Catheter ablation for ventricular arrhythmias.Arrhythm Electrophysiol Rev.2013 Apr;2(1):45–52. doi:10.15420/aer.2013.2.1.45Arnett DK, Blumenthal RS, Albert MA, et al.2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2019 Sep 10;140(11):e596-e646. doi:10.1161/CIR.0000000000000678Marine JE.Nonsustained ventricular tachycardia in the normal heart: risk stratification and management.Card Electrophysiol Clin. 2016;8(3):525-543. doi:10.1016/j.ccep.2016.04.003Marine JE, Shetty V, Chow GV, et al.Prevalence and prognostic significance of exercise-induced nonsustained ventricular tachycardia in asymptomatic volunteers: BLSA (Baltimore Longitudinal Study of Aging).J Am Coll Cardiol. 2013;62(7):595-600. doi:10.1016/j.jacc.2013.05.026
Marine JE.Nonsustained ventricular tachycardia in the normal heart: risk stratification and management.Card Electrophysiol Clin.2016 Sep;8(3):525-43. doi:10.1016/j.ccep.2016.04.003
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al.2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society.Circulation. 2018;138(13):e190-e252. doi:10.1016/j.hrthm.2017.10.035
Cronin EM, Bogun FM, Maury P, et al.2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.Heart Rhythm.2020 Jan;17(1):e2-e154. doi:10.1016/j.hrthm.2019.03.002
Lin CY, Chang SL, Chung FP, et al.Long-term outcome of non-sustained ventricular tachycardia in structurally normal hearts.PLoS One. 2016;11(8):e0160181. doi:10.1371/journal.pone.0160181
Harris P, Lysitsas D.Ventricular arrhythmias and sudden cardiac death.BJA Educ. 2016;16(7):221-229. doi:10.1093/bjaed/mkv056
Jamil HA, Mohammed SA, Gierula J, et al.Prognostic significance of incidental nonsustained ventricular tachycardia detected on pacemaker interrogation.Am J Cardiol. 2019;123(3):409-413. doi:10.1016/j.amjcard.2018.10.040
Hammersley DJ, Halliday BP.Sudden cardiac death prediction in non-ischemic dilated cardiomyopathy: a multiparametric and dynamic approach.Curr Cardiol Rep. 2020;22(9):85. doi:10.1007/s11886-020-01343-9
Lin CY, Chang SL, Chung FP, et al.Long-term outcome of non-sustained ventricular tachycardia in structurally normal hearts.PLoS One. 2016;11(8):e0160181. Published 2016 Aug 22. doi:10.1371/journal.pone.0160181
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al.2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.Eur Heart J. 2015;36(41):2793-2867. doi:10.1093/eurheartj/ehv316
Ommen SR, Mital S, Burke MA, et al.2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2020;142(25):e558–e631. doi:10.1161/CIR.0000000000000937
Wang C, Ju W, Chen H, et al.The clinical and electrophysiological characteristics of nonsustained repetitive monomorphic ventricular tachycardia from the left His‐Purkinje system.Pacing Clin Electrophysiol. 2020;43(10):1149-1155. doi:10.1111/pace.14055
UpToDate.Ventricular tachycardia in the absence of apparent structural heart disease.
Kohno R, Abe H, Benditt DG.Ambulatory electrocardiogram monitoring devices for evaluating transient loss of consciousness or other related symptoms.J Arrhythm. 2017 May;33(6):583-589. doi:10.1016/j.joa.2017.04.012
Li X, Yao Y, Chen Z, et al.Thyroid‐stimulating hormone within the normal range and risk of major adverse cardiovascular events in nonischemic dilated cardiomyopathy patients with severe left ventricular dysfunction.Clin Cardiol. 2019;42(1):120-128. doi:10.1002/clc.23117
ScienceDirect.Sustained ventricular tachycardia.
Katritsis DG, Zareba W, Camm AJ.Nonsustained ventricular tachycardia.J Am Coll Cardiol. 2012;60(20):1993-2004. doi:10.1016/j.jacc.2011.12.063
Nof E, Stevenson WG, John RM.Catheter ablation for ventricular arrhythmias.Arrhythm Electrophysiol Rev.2013 Apr;2(1):45–52. doi:10.15420/aer.2013.2.1.45
Arnett DK, Blumenthal RS, Albert MA, et al.2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2019 Sep 10;140(11):e596-e646. doi:10.1161/CIR.0000000000000678
Marine JE.Nonsustained ventricular tachycardia in the normal heart: risk stratification and management.Card Electrophysiol Clin. 2016;8(3):525-543. doi:10.1016/j.ccep.2016.04.003
Marine JE, Shetty V, Chow GV, et al.Prevalence and prognostic significance of exercise-induced nonsustained ventricular tachycardia in asymptomatic volunteers: BLSA (Baltimore Longitudinal Study of Aging).J Am Coll Cardiol. 2013;62(7):595-600. doi:10.1016/j.jacc.2013.05.026
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?
